<DOC>
	<DOCNO>NCT02344017</DOCNO>
	<brief_summary>The purpose first-in-man study evaluate safety , tolerability pharmacokinetics ODM-204 patient metastatic castration-resistant prostate cancer .</brief_summary>
	<brief_title>Safety Pharmacokinetics ODM-204 Patients With Metastatic Castration-Resistant Prostate Cancer</brief_title>
	<detailed_description>The safety profile ODM-204 explore together pharmacokinetics , pharmacodynamics tumour response treatment ODM-204 recommend dose regimen clinical study . The pharmacokinetic property ODM-204 evaluate single multiple dose administration different dose level .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<criteria>Written inform consent ( IC ) obtain . Male age â‰¥ 18 year . Histologically cytologically confirm adenocarcinoma prostate . Ongoing GnRH agonist antagonist therapy , bilateral orchiectomy . Progressive metastatic disease Adequate bone marrow , hepatic , renal function Acceptable regular bowel movement without GI disorder procedure may interfere absorption study treatment Ability swallow study treatment History pituitary adrenal dysfunction . Known brain metastasis . Active infection medical condition would make prednisone ( corticosteroid ) contraindicate . Uncontrolled hypertension Clinically significant heart disease Prolonged QTc interval</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>